Phibro Animal Health Corp banner

Phibro Animal Health Corp
SWB:PB8

Watchlist Manager
Phibro Animal Health Corp Logo
Phibro Animal Health Corp
SWB:PB8
Watchlist
Price: 30.8 EUR 0.65%
Market Cap: €1.2B

Wall St Price Targets

PB8 Price Targets Summary
Phibro Animal Health Corp

Wall Street analysts forecast PB8 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PB8 is 35.46 EUR with a low forecast of 29.44 EUR and a high forecast of 42.85 EUR.

Lowest Forecast
Price Target
29.44 EUR
4% Downside
Average Forecast
Price Target
35.46 EUR
15% Upside
Highest Forecast
Price Target
42.85 EUR
39% Upside
Phibro Animal Health Corp Competitors:
Price Targets
SNNP
Srinanaporn Marketing PCL
21% Upside

Revenue
Forecast

5% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
5% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 5 years is 6%.

Gross Profit
Forecast

7% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
7% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 3 years is 12%.

Operating Income
Forecast

8% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss
8% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-10%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 5 years is 17%.

Pre-Tax Income
Forecast

14% / Year
Past Growth
44% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
14% / Year
Past Growth
44% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 44%.

Net Income
Forecast

16% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
16% / Year
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 16%. The projected CAGR for the next 5 years is 33%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is PB8's stock price target?
Price Target
35.46 EUR

According to Wall Street analysts, the average 1-year price target for PB8 is 35.46 EUR with a low forecast of 29.44 EUR and a high forecast of 42.85 EUR.

What is the Revenue forecast for Phibro Animal Health Corp?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 5 years is 6%.

What is the Gross Profit forecast for Phibro Animal Health Corp?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 7%. The projected CAGR for the next 3 years is 12%.

What is the Operating Income forecast for Phibro Animal Health Corp?
Projected CAGR
17%

Over the last 13 years, the compound annual growth rate for Operating Income has been 8%. The projected CAGR for the next 5 years is 17%.

What is the Pre-Tax Income forecast for Phibro Animal Health Corp?
Projected CAGR
44%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 44%.

What is the Net Income forecast for Phibro Animal Health Corp?
Projected CAGR
33%

Over the last 13 years, the compound annual growth rate for Net Income has been 16%. The projected CAGR for the next 5 years is 33%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett